Rheumatoid arthritis is defi ned as persistent joint infl ammation that is marked as joint pain, stiffness, and swelling, resulting in progressive destruction of cartilage in the joints. 2 Although rheumatoid arthritis primarily targets the synovial lining of joints, it has extra-articular effects, including the lungs, heart, and blood vessels. 3 If untreated, rheumatoid arthritis can lead to permanent joint damage, a decrease in quality of life, and disability. Approximately 20% of patients are retired completely or partially within 2 years of disease onset, and 50% of patients are unable to work after 10 years. 4 Furthermore, rheumatoid arthritis may reduce life expectancy between 2 and 18 years. 5 As a result, rheumatoid arthritis is a burden on patients' quality of life and health care systems.
TRADITIONAL APPROACH
Pharmacologic approaches have traditionally relied on steroids (eg, prednisone, methylprednisolone), nonsteroidal anti-infl ammatory drugs (eg, aspirin, ibuprofen), and diseasemodifying antirheumatic drugs (DMARDs) (eg, methotrexate [MXT] , hydroxychloroquine). 6 Disease-modifying antirheumatic drugs are commonly used in patients newly diagnosed with rheumatoid arthritis. 6 Because of its safety profi le, long-term effectiveness, and low cost, MTX is the most commonly used DMARD. 6 Other DMARDs used less frequently include lefl unomide, gold salts, azathioprine, cyclosporine, and minocycline.
Unfortunately, some patients with rheumatoid arthritis fail to respond to DMARD therapy, with up to one-third of patients discontinuing DMARD therapy due to a lack of effi cacy. 7, 8 Thus, newer treatments involving the use of biologicals may provide alternatives to traditional DMARD therapy.
BIOLOGICAL THERAPIES
Although the precise etiology of rheumatoid arthritis is unknown, evidence exists that proinfl ammatory cytokines, such as tumor necrosis factor ␣ (TNF␣), interleukin-1 (IL-1), and interleukin-6 (IL-6), play a role in the pathogenesis of rheumatoid arthritis. 9, 10 Thus, biologic agents have been developed to target specifi c infl ammatory mediators of tissue damage. The use of biologics has led to improved outcomes. Although expensive, biologics appear to be cost-effective due to the clinical benefi ts patients experience. 
TNF Antagonists
Physiological responses to TNF␣ include induction of proinfl ammatory cytokines (IL-1 and IL-6) and increasing the synthesis of prostaglandins. However, concern exists regarding the association between TNF␣ inhibition and the occurrence of serious infections and the development of lymphoma. Histoplasmosis, aspergillosis, listeriosis, and cytomegalovirus have been described in several case reports of patients receiving TNF␣ inhibitor therapy. 11 Black box warnings include fungal infection, mycobacterial infection, viral infection, neoplastic disease, and tuberculosis. Heart failure and sepsis are absolute contraindications.
Infl iximab is a chimeric IgG1 molecule with a mouse antibody against TNF␣. Infl iximab binds to the soluble and membrane-bound TNF␣ and is commonly administered with MTX to suppress antibody production against the mouse portion of the molecule. Infl iximab is approved for rheumatoid arthritis at a dose of 3 mg/kg infused intravenously over 2 hours, followed by additional doses at 2 and 6 weeks and then every 8 weeks indefi nitely. The infl iximab dose may be increased in the absence of clinical response. In MTX-naive patients with disease duration Ͻ3 years, concurrent use of infl iximab and MTX reduced the signs and symptoms of rheumatoid arthritis and improved physical function to a greater extent than MTX monotherapy. 12 Infusion reactions (eg, headache, nausea, urticaria, and anaphylaxis) regularly occur with the administration of infl iximab.
Approximately 10% of patients treated with infl iximab develop antibodies, and these patients are more likely to have infusion reactions. However, development of infl iximab antibodies was lower among patients receiving concurrent immunosuppressive therapy (eg, azathioprine or methotrexate). Minor reactions usually respond to antihistamines and decreasing the infusion rate. 13 Etanercept is a dimer composed of 2 recombinant 14 Adalimumab is less antigenic than infl iximab or tanercept because it is a recombinant human IgG1 monoclonal antibody. Adalimumab blocks TNF␣ receptors, neutralizing the activity of TNF␣. In the treatment of rheumatoid arthritis, adalimumab is associated with a rapid onset of clinical effect (24 hours to 1 week), with a peak effi cacy at 1 to 2 weeks after a single 40-mg subcutaneous dose. In addition to reducing the symptoms of rheumatoid arthritis, adalimumab reduces disease progression, as evidenced by radiographic progression slowing. Combined therapy with MTX has resulted in greater improvements than monotherapy. 15 It has a half-life of up to 20 hours and can be selfadministered subcutaneously every 2 weeks at 40 mg per dose, with a dosage increase of up to 40 mg per week if necessary. Patients with an inadequate response to MTX who received a concomitant 40-mg subcutaneous dose of adalimumab every other week for 1 year had signifi cantly less progression and erosion than did patients who received MTX alone. 16 Local skin injection reactions were the most common side effect.
Certolizumab pegol is a recombinant, pegylated, humanized Fab fragment of anti-TNF␣ monoclonal antibody that neutralizes membraneassociated and soluble human TNF␣. Unlike etanercept, infl iximab, and adalimumab, certolizumab pegol does not cause antibody-dependent cell-mediated cytoxotoxicyt.
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A 400-mg subcutaneous dose is given in two 200 mg injections at weeks 0, 2, and 4, and then a 200-mg subcutaneous dose is given every other week. For patients who did not have a positive response to MTX, the addition of certolizumab led to a positive response in 53% of patients compared with a 13% response for recipients of MTX only. No further benefi t is seen with doses higher than 400 mg administered every 2 weeks. 18 In patients who failed at least 1 DMARD, monotherapy with certolizumab led to a positive response in 45.5% of patients. Optimal response is reported after 16 weeks of therapy. 18 Patients must be evaluated for latent tuberculosis infection before treatment. The most common adverse reactions leading to discontinu-■ pharmacology update ation of certolizumab pegol were tuberculosis infections, pyrexia, urticarial, pneumonia, and rash.
Golimumab is a monoclonal antibody with a humanderived antibody against TNF␣. It binds the soluble and membrane forms of TNF␣. Among patients with symptoms of rheumatoid arthritis despite MTX treatment, a 50-mg subcutaneous dose of golimumab every 4 weeks led to a 20% improvement in 55% patients; 33% of patients who received a placebo plus MTX met the endpoint. 19 Due to a longer half-life, golimumab is administered less frequently than adalimumab and etanercept. 20 
IL-1 Inhibitors
Anakinra is a recombinant human IL-1 receptor antagonist that competitively inhibits the binding of IL-1 to its receptor. IL-1 is a major proinfl ammatory cytokine and causes cartilage degradation. A 100-mg subcutaneous dose is administered every 24 hours. Higher doses do not result in an increased response. Anakinra is renally eliminated, with a half-life up to 6 hours. Anakinra should not be administered with anti-TNF␣ therapies because an increased infection risk exists with minimal clinical benefi t. Injection site reactions such as erythema, edema, and infl ammation are the most common side effects, which usually occur during the fi rst 4 weeks of treatment. During clinical trials, the infection incidence was 40% in patients treated with anakinra and 35% in patients treated with a placebo. Reported infections included upper respiratory tract infections (13%), sinusitis (6%), and infl uenza-like symptoms (5%).
T-cell Costimulation Blocker
Abatacept (CTLA4-Ig) is a fusion protein that blocks the binding of CD80/CD86 and prevents the second costimulatory signal that is required for optimal T-cell activation. Although the mechanism is unclear, Abatacept decreases IL-6, rheumatoid factor, ■ pharmacology update C-reactive protein, and TNF␣ in patients with rheumatoid arthritis. A therapeutic response after administration of a 10-mg/ kg dose of abatacept in combination with MTX was seen in 14% of patients, whereas 2% of patients who received a placebo and MTX had a therapeutic response. 21 Although abatacept may be used with MTX, concurrent use of abatacept and TNF-inhibitors is not recommended.
A 125-mg subcutaneous dose of abatacept is administered within a day after a single intravenous loading dose, then weekly thereafter. Infusion doses are based on weight but are administered intravenously over 30 minutes twice every 2 weeks (ie, a dose at weeks 0, 2, and 4) and then every 4 weeks beginning at week 8. Infusion reactions occur within 1 hour of the start of the infusion, and most reactions are mild to moderate. Medications that decrease mucociliary function or cough refl ex can facilitate the ability of bacteria to enter the lungs and proliferate. Of the patients with chronic obstructive pulmonary disease who received abatacept, 43% had an exacerbation, cough, rhonchi, or dyspnea compared with 24% of patients who received a placebo. 22 Headache and dizziness may be associated with the infusion and are reported at a rate of Ͻ2%.
B-cell Depleting Agent
Rituximab is a chimeric murine/human IgG1 monoclonal antibody that binds specifically to CD20, which results in the rapid and sustained depletion of B-cells. The US Food and Drug Administration approved the use of rituximab in combination with MTX to reduce the signs and symptoms of rheumatoid arthritis in adults with an inadequate response to TNF␣ antagonist therapies. A 1000-mg intravenous dose is administered on days 1 and 15. Black box warnings include infusionrelated reactions because approximately 80% of fatal infusion reactions occur with the fi rst infusion of rituximab. All patients should receive diphenhydramine, acetaminophen, and possibly corticosteroids (100 mg of methylprednisolone intravenously or its equivalent) as premedication. In clinical trials, adverse events reported include fever (53%), chills (33%), peripheral edema (16%), night sweats (15%), fatigue (13%), pain (12%), and fl ushing (5%).
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IL-6 Inhibitor
Tocilizumab is a humanized IL-6 receptor-inhibiting monoclonal antibody, which competes with IL-6 for binding to the IL-6 receptor. IL-6 correlates with disease severity, and patients with rheumatoid arthritis have elevated IL-6 concentrations in serum and synovial fl uid. Tocilizumab binds to soluble and membrane-bound IL-6 receptors and inhibits IL-6 mediated signaling through these receptors, and thus attenuates rheumatoid arthritis associated symptoms and joint damage.
IL-6 is produced by synovial and endothelial cells, leading to local production of IL-6 in joints affected by infl ammatory processes such as rheumatoid arthritis. The use of tocilizumab for patients with no prior inadequate response to TNF␣ antagonists is not recommended. A 4-mg/ kg intravenous dose of tocilizumab is administered over 1 hour every 4 weeks. If needed, the dose can be increased to 8 mg/kg intravenously every 4 weeks (800 mg per dose maximum). Adverse reactions include upper respiratory tract infections, nasopharyngitis, opportunistic infections, pneumonia, urinary tract infections, and tuberculosis.
INVESTIGATIONAL MEDICATIONS
Denosumab is a fully human, highly specifi c, monoclonal antibody against RANKL. Denosumab decreases RANKL activation of RANKL receptors on the surface of osteoclasts, resulting in a down regulation of osteoclast activity, resulting in a reduction of bone resorption. 24 The addition of twiceyearly injections of denosumab to ongoing MTX treatment in- Syk kinase is a cytoplasmic tyrosine kinase involved in upregulation of TNF␣ and IL-6 synthesis. Thus, Syk kinase inhibitors may play a role in the treatment of rheumatoid arthritis. Fostamatinib is an oral inhibitor that is converted to an active drug, which is a potent Syk kinase inhibitor. 26 One phase II trial demonstrated that patients in the Fostamatinib group had signifi cantly better outcomes than patients in the placebo group (67% vs 35%, respectively). 26 Adverse events arising during the study included diarrhea, upper respiratory tract infections, and neutropenia. It was concluded that, in this phase II study involving patients who had active rheumatoid arthritis despite treatment with MTX, the addition of a Syk kinase inhibitor led to reduced disease activity ( Table 2) .
THE BOTTOM LINE
Patients who take biologic DMARDs typically see improvements after the fi rst or second dose. Abatacept and rituximab may be useful alternatives in patients with longstanding rheumatoid arthritis who have an inadequate response to combination therapy with TNF␣ antagonists plus MTX. Several new rheumatoid arthritis treatments have novel mechanisms of action and are at different stages of development. Overall, the use of biologics in the treatment of rheumatoid arthritis has led to improved outcomes, and although biologics are costly, they remain cost-effective due to the clinical benefi ts patients may experience.
